6 recruiting, 2 active not recruiting, 2 completed, 2 terminated. 13 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Recruiting 6, Active not recruiting 2, Completed 2, Terminated 2, Withdrawn 1 |
| Phase 2 | 8 | Recruiting 4, Terminated 2, Active not recruiting 1, Withdrawn 1 |
Follow elacestrant: new trials by email Literature Review of elacestrant trials Research Report on elacestrant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elacestrant in Advanced Triple Positive Breast Cancer Elacestrant, Trastuzumab, Pertuzumab - ER Positive, HER2 Positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | NYU Langone Health | 50 | 2026-05-13 | 2026-05-28 |
| ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer Elacestrant, Trastuzumab Deruxtecan - Metastatic Breast Cancer, HER2 Low Breast Carcinoma | Phase 1 / Phase 2 | Recruiting | Kristina A. Fanucci | 65 | 2025-11-17 | 2026-06-10 |
| Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer Elacestrant, DC1 native/mutated ESR1 - Breast Cancer Metastatic Breast Cancer, HER2-negative Breast Cancer | Phase 1 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 18 | 2024-11-04 | 2026-08-18 |
| A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer MEN2312, Elacestrant - Advanced Breast Cancer | Phase 1 | Recruiting | Stemline Therapeutics, Inc. | 240 | 2024-10-25 | 2026-08-07 |
| BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors BGB-43395, Fulvestrant, Letrozole - Advanced Solid Tumor, Advanced Breast Cancer | Phase 1 | Recruiting | BeOne Medicines | 433 | 2023-12-01 | 2026-10-15 |
| A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer Elacestrant, Onapristone - Breast Cancer | Phase 1 / Phase 2 | Withdrawn | Context Therapeutics Inc. | 2023-06-01 | 2025-04-22 | |
| Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer Elacestrant, Alpelisib, Everolimus - Breast Cancer, Metastatic Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Stemline Therapeutics, Inc. | 435 | 2023-01-24 | 2026-06-12 |
| Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer EP0062, Elacestrant, Everolimus - Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | Ellipses Pharma | 95 | 2023-01-11 | 2026-06-22 |
| Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer Elacestrant, Onapristone - Breast Cancer | Phase 1 / Phase 2 | Terminated | Context Therapeutics Inc. | 4 | 2022-12-02 | 2026-07-21 |
| Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer Elacestrant, Abemaciclib - Breast Neoplasms, Brain Neoplasms | Phase 1 / Phase 2 | Recruiting | Stemline Therapeutics, Inc. | 73 | 2022-08-31 | 2026-10-09 |
| Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer Abemaciclib, Elacestrant - Breast Cancer | Phase 1 / Phase 2 | Terminated | Criterium, Inc. | 5 | 2022-04-21 | 2026-03-31 |
| Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer RAD1901 - Metastatic Breast Cancer | Phase 1 | Completed | Stemline Therapeutics, Inc. | 16 | 2016-04-01 | 2022-08-18 |
| A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer Elacestrant - Advanced ER+, HER2-Negative Breast Cancer | Phase 1 | Completed | Stemline Therapeutics, Inc. | 57 | 2015-01-01 | 2022-08-18 |
Breast Neoplasms (11) · Brain Diseases (1) · Brain Neoplasms (1) · Breast Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1)
Stemline Therapeutics, Inc. (5) · Context Therapeutics Inc. (2) · BeOne Medicines (1) · Criterium, Inc. (1) · Ellipses Pharma (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Kristina A. Fanucci (1) · NYU Langone Health (1)
United States (12) · Spain (4) · Belgium (3) · France (3) · South Korea (3) · United Kingdom (3) · Australia (2) · Brazil (2) · Italy (2) · Turkey (Türkiye) (2) · Argentina (1) · China (1) · Germany (1) · Greece (1) · Israel (1)
Aixa Soyano Muller, MD (1) · Douglas K Marks, MD (1) · Elisabeth GE de Vries, MD (1) · Kristina Fanucci, MD (1) · Peter Kabos, MD (1)
2015 (1), 2023 (1)